[{"Physician_Profile_ID": "35650", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Amgen Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CA", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000203", "Total_Amount_of_Payment_USDollars": "5000.00", "Date_of_Payment": "02/05/2015", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "297533118", "Name_of_Associated_Covered_Drug_or_Biological1": "Repatha", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "LAPLACE2 Combination Therapy", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "35650", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "1414.00", "Date_of_Payment": "08/26/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106110930", "Name_of_Associated_Covered_Drug_or_Biological1": "Actos", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "35650", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Takeda Development Center Americas, Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "IL", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000338", "Total_Amount_of_Payment_USDollars": "825.99", "Date_of_Payment": "08/26/2013", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "106110927", "Name_of_Associated_Covered_Drug_or_Biological1": "Actos", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "35650", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Amgen Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CA", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000203", "Total_Amount_of_Payment_USDollars": "151.88", "Date_of_Payment": "06/07/2015", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "297533162", "Name_of_Associated_Covered_Drug_or_Biological1": "Repatha", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "MENDEL2 Monotherapy", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "35650", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "GlaxoSmithKline, LLC.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005449", "Total_Amount_of_Payment_USDollars": "92.20", "Date_of_Payment": "05/28/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "208680858", "Name_of_Associated_Covered_Drug_or_Biological1": "", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "35650", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Amgen Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CA", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000203", "Total_Amount_of_Payment_USDollars": "79.66", "Date_of_Payment": "06/07/2015", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "297533160", "Name_of_Associated_Covered_Drug_or_Biological1": "Repatha", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "MENDEL2 Monotherapy", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "35650", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Amgen Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CA", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000203", "Total_Amount_of_Payment_USDollars": "43.64", "Date_of_Payment": "08/30/2015", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "297532754", "Name_of_Associated_Covered_Drug_or_Biological1": "Repatha", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Consistent and Clinically Equivalent LDL-C Reduction with Q2W and QM in Phase 3", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "35650", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "Amgen Inc.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "CA", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000000203", "Total_Amount_of_Payment_USDollars": "15.94", "Date_of_Payment": "10/12/2015", "Form_of_Payment_or_Transfer_of_Value": "In-kind items and services", "Record_ID": "297532868", "Name_of_Associated_Covered_Drug_or_Biological1": "Repatha", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "Efficacy and Safety of the PCSK9 Inhibitor Evolocumab (AMG 145) in Patients with Type 2 Diabetes", "Research_Information_Link": "", "Context_of_Research": ""}, {"Physician_Profile_ID": "35650", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name": "GlaxoSmithKline, LLC.", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State": "NC", "Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID": "100000005449", "Total_Amount_of_Payment_USDollars": "1.08", "Date_of_Payment": "05/28/2014", "Form_of_Payment_or_Transfer_of_Value": "Cash or cash equivalent", "Record_ID": "208680862", "Name_of_Associated_Covered_Drug_or_Biological1": "", "Name_of_Associated_Covered_Drug_or_Biological2": "", "Name_of_Study": "A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events  MACE", "Research_Information_Link": "", "Context_of_Research": ""}]